GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed last ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

Joining Ramu NiCo as an Asset Protection Officer is a blessing not just for Kenneth Kowi but for his whole family.